Treatment for female external genital lichen sclerosus: from standards to innovations

1. Jones R.W., Scurry J., Neill S., MacLean A.B. Guidelines for the follow-up of women with vulvar lichen sclerosus in specialist clinics. Am. J. Obstet. Gynecol. 2008; 198(5): 496. e1-496. e3. https://dx.doi.org/10.1016/j.ajog.2007.05.031.
2. Tran D.A., Tan X., Macri C.J., Goldstein A.T., Fu S.W. Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int. J. Biol. Sci. 2019; 15(7): 1429-39. https://dx.doi.org/10.7150/ijbs.34613.
3. Howard A., Dean D., Cooper S., Kirtshig G., Wojnarowska F. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Australas. J. Dermatol. 2004; 45(1): 12-5. https://dx.doi.org/10.1111/j.1440-0960.2004.00026.x.
4. Clifton M.M., Garner I.B., Kohler S., Smoller B.R. Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus: evidence for loss of androgen receptors in lesional epidermis. J. Am. Acad. Dermatol. 1999; 41(1): 43-6. https://dx.doi.org/10.1016/s0190-9622 (99)70404-4.
5. Higgins C.A., Cruickshank M.E. A population-based case-control study of aetiological factors associated with vulvar lichen sclerosus. J. Obstet. Gynaecol. 2012; 32(3): 271-5. https://dx.doi.org/10.3109/01443615.2011.649320.
6. Nasca M.R., Lacarrubba F., Micali G. Human papillomavirus infection and lichen sclerosus: coincidence or link? Int. J. Dermatol. 2018; 57(5): 611-24. https://dx.doi.org/10.1111/ijd.13933.
7. Aidé S., Lattario F.R., Almeida G., do Val I.C., da Costa Carvalho M. Epstein-Barr virus and human papillomavirus infection in vulvar lichen sclerosus. J. Low. Genit. Tract. Dis. 2010; 14(4): 319-22. https://dx.doi.org/10.1097/LGT.0b013e3181d734f1.
8. Eisendle K., Grabner T., Kutzner H., Zelger B. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch. Dermatol. 2008; 144(5): 591-8. https://dx.doi.org/10.1001/archderm.144.5.591.
9. Реуцкая М.А., Кулинич С.И. Новые подходы к диагностике и лечению заболеваний вульвы. Сибирский медицинский журнал. 2011; 6: 277-9. [Reutskaya M.A., Kulinich S.I. Vulvar diseases and their interrelation with genital infection. Siberian Medical Journal. 2011; 6: 277-9 (in Russian)].
10. Kirtschig G., Cooper S., Aberer W., Günthert A, Becker K., Jasaitiene D. et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J. Eur. Acad. Dermatol. Venereol. 2017;31(2): e81-3. https://dx.doi.org/10.1111/jdv.13740.
11. Kravvas G., Shim T.N., Doiron P.R., Freeman A., Jameson C., Minhas S. et al. The diagnosis and management of male genital lichen sclerosus: a retrospective review of 301 patients. J. Eur. Acad. Dermatol. Venereol. 2018; 32(1): 91-5. https://dx.doi.org/10.1111/jdv.14488.
12. Marfatia Y., Surani A., Baxi R. Genital lichen sclerosus et atrophicus in females: An update. Indian. J. Sex. Transm. Dis. AIDS. 2019; 40(1): 6-12. https://dx.doi.org/10.4103/ijstd.IJSTD_23_19.
13. Sherman V., McPherson T., Baldo M., Salim A., Gao X.H., Wojnarowska F. The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study. J. Eur. Acad. Dermatol. Venereol. 2010; 24(9): 1031-4. https://dx.doi.org/10.1111/j.1468-3083.2010.03572.x.
14. Virgili A., Borghi A., Cazzaniga S., Di Landro A., Naldi L., Minghetti S. et al.; GLS Italian Study Group. New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases. J. Eur. Acad. Dermatol. Venereol. 2017; 31(4): 699-704. https://dx.doi.org/10.1111/jdv.13867.
15. Powell J.J., Wojnarowska F. Lichen sclerosus. Lancet. 1999; 353(9166): 1777-83. https://dx.doi.org/10.1016/S0140-6736(98)08228-2
16. Burns P.B., Rohrich R.J., Chung K.C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 2011; 128(1): 305-10. https://dx.doi.org/10.1097/PRS.0b013e318219c171.
17. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд. М.: Деловой экспресс; 2016. 768 с. [Federal clinical guidelines. Dermatovenerology 2015: Diseases of the skin. Sexually transmitted infections 5th edition revised and supplemented. Russian Federation. Moscow Business express; 2016. 768 p.(in Russian)].
18. Lewis F.M., Tatnall F.M., Velangi S.S., Bunker C.B., Kumar A., Brackenbury F. et al. British Association of Dermatologists guidelines for the management of lichen sclerosus. Br. J. Dermatol. 2018; 178(4): 839-53. https://dx.doi.org/10.1111/bjd.16241
19. Virgili A., Gorghi A., Toni G., Minghetti S., Corazza M. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br. J. Dermatol. 2014; 171(2): 388-96. https://dx.doi.org/10.1111/bjd.12910.
20. Ventolini C., Swenson K.M., Galloway M.L. Lichen sclerosus: a 5-year follow-up after topical, subdermal, or combined therapy. J. Low. Genit. Tract. Dis. 2012; 16(3): 271-4.
21. Baggish M.S., Ventolini C. Lichen sclerosus: Subdermal steroid injection therapy. A large, long-term follow-up study. J. Gynecol. Surg. 2006; 22(4):, 137-41. https://dx.doi.org/10.1089/gyn.2006.22.137.
22. Von Krogh G., Dahlman-Ghozlan K., Syrjanen S. Potential human papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus. J. Eur. Acad. Dermatol. Venereol. 2002; 16(2): 130-3. https://dx.doi.org/10.1046/j.1468-3083.2002.00420.x
23. Strittmatter H.J., Hengge U.R., Blecken S.R. Calcineurin antagonists in vulvar lichen sclerosus. Arch. Gynecol. Obstet. 2006; 274(5): 266-70. https://dx.doi.org/10.1007/s00404-006-0151-1.
24. Funaro D., Lovett A., Leroux N., Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J. Am. Acad. Dermatol. 2014; 71(1): 84-91. https://dx.doi.org/10.1016/j.jaad.2014.02.019.
25. Hodgins M.B., Mackie R.M., Spike R.C., Maclean A. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br. J. Obstet. Gynaecol. 1998; 105(2): 216-22. https://dx.doi.org/10.1111/j.1471-0528.1998.tb10056.x.
26. Bracco G.L., Carli P., Sonni L., Maestrini G., De Marco A., Taddei G.L., Cattaneo A. Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. J. Reprod. Med. 1993; 38(1):37-40.
27. Preti M., Vieira-Baptista P., Digesu G.A., Bretschneider C.E., Damaser M., Demirkesen O. et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document. Neurourol. Urodyn. 2019; 38(3): 1009-23.https://dx.doi.org/10.1097/LGT.0000000000000462.
28. Bizjak Ogrinc U., Senčar S., Luzar B., Lukanović A. Efficacy of non-ablative laser therapy for lichen sclerosus: a randomized controlled trial. J. Obstet. Gynaecol. Can. 2019; 41(12): 1717-25. https://dx.doi.org/10.1016/j.jogc.2019.01.023
29. Lee A., Lim A., Fischer G. Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus. Australas. J. Dermatol. 2016; 57: 39-43. https://dx.doi.org/10.1111/ ajd.12305.
30. Карабут М.М., Гладкова Н.Д., Фельдштейн Ф.И. Фракционный лазерный фототермолиз в лечении кожных дефектов: возможности и эффективность (обзор). Современные технологии в медицине. 2016; 8(2): 98-108. [Karabut М.М., Gladkova N.D., Feldchtein F.I. Fractional laser photothermolysis in the treatment of skin defects: possibilities and effectiveness (review). Sovremennye tehnologii v medicine 2016; 8(2): 98–108 (in Russian)].
31. Arroyo C., Perez A., Muñoz L. Treatment of lichen sclerosus with Erbium:YAG Laser – an option to consider. J. Laser Health Academy. 2018; 1: S14. Available at: https://www.laserandhealthacademy.com/en/library/4725/cesar-arroyo-er-yag-treatment-of-lichen-sclerosus
32. Gómez-Frieiro M., Laynez-Herrero E. Use of Er:YAG Laser in the treatment of vulvar lichen sclerosus. Int. J. Women's Dermatol. 2019; 5(5): 340-4. https://dx.doi.org/10.1016/j.ijwd.2019.05.007.
33. Windahl T. Is carbon dioxide laser treatment of lichen sclerosus effective in the long run?, Scandinavian J. Urol. Nephrol. 2006; 40(3): 208-11. https://dx.doi.org/10.1080/00365590600589666.
34. Pagano T., Conforti A., Buonfantino C., Schettini F., Vallone R., Gallo A. et al. Effect of rescue fractional microablative CO2 laser on symptoms and sexual dysfunction in women affected by vulvar lichen sclerosus resistant to long-term use of topic corticosteroid: a prospective longitudinal study. Menopause. 2020; 27(4): 418-22. https://dx.doi.org/10.1097/GME.0000000000001482.
35. Хашукоева А.З., Отдельнова О.Б., Купеева Е.С. Фотодинамическая терапия дистрофических заболеваний вульвы в сочетании с папилломавирусной инфекцией. Лечение и профилактика. 2012; 1: 78-80. [Khashukoeva A.Z, Kupeeva E.S., Otdelnova O.B. PDT of dystrophic vulvar diseases in combination with papillomavirus infection, Treatment and prevention. 2012; 1: 78-80 (in Russian)].
36. Новикова Е.Г., Соколов В.В., Сидорова И.С., Чулкова Е.А. Флюоресцентная диагностика и фотодинамическая терапия фоновых и предраковых заболеваний вульвы с применением 20% мази «Аласенс». Российский онкологический журнал. 2009; 2: 12-9. [Novikova E.G., Sokolov V.V., Sidorova I.S., Chulkova E.A. Fluorescence diagnosis and photodynamic therapy of background and pre-cancer vulvar diseases with 20% Alasens ointment, Rossiiskii onkologicheskii zhurnal. 2009; 2: 12-9. (in Russian)].
37. Shi L., Miao F., Zhang L.L., Zhang G.L.,Wang P.R., Ji J. et al. Comparison of 5-aminolevulinic acid photodynamic therapy and clobetasol propionate in treatment of vulvar lichen sclerosus. Acta Derm. Venereol. 2016; 96(5): 684-8. https://dx.doi.org/10.2340/00015555-2341.
38. Krapf J.M., Mitchell L., Holton M.A., Goldstein A.T. Vulvar Lichen Sclerosus: Current Perspectives. Int. J. Womens Health. 2020; 12: 11-20. https://dx.doi.org/10.2147/IJWH.S191200.
39. Marx R. Platelet-rich plasma (PRP): What is PRP and what is not PRP? Implant. Dent. 2001; 10(4): 225-8. https://dx.doi.org/10.1097/00008505-200110000-00002.
40. Аполихина И.А., Соколова А.В., Педанов А.М., Иванова Е.В. Применение богатой тромбоцитами плазмы в эстетической гинекологии. Учебное пособие. М.: Меркурий; 2019. 100 с. [Apolikhina I.A, Sokolova A.V., Pedanov A.M., Ivanova E.V. The use of platelet-rich plasma in aesthetic gynecology. Moscow: Mercury; 2019. 100 p. (in Russian)].
41. Tedesco M., Pranteda G., Chichierchia G., Paolino G., Latini A., Orsini D. et al. The use of PRP (platelet‐rich plasma) in patients affected by genital lichen sclerosus: clinical analysis and results. J. Eur. Acad. Dermatol. Venereol. 2019; 33(2): e58-9. https://dx.doi.org/10.1111/jdv.15190.
42. Turzi Antoine & Regen Lab team. PRP standardisation & cells therapies. (PRP – Platelet Rich Plasma). Biobridge Foundation Editions; 3 Jan. 2018. 96p.
43. Casabona F., Priano V., Vallerino V., Cogliandro A., Lavagnino G. New surgical approach to lichen sclerosus of the vulva: the role of adipose-derived mesenchymal cells and platelet-rich plasma in tissue regeneration. Plast. Reconstr. Surg. 2010; 126(4): 210e-211e. https://dx.doi.org/10.1097/PRS.0b013e3181ea9386.
44. Boero V., Brambilla M., Sipio E., Liverani C.A., Di Martino M., Agnoli B. et al. Vulvar lichen sclerosus: a new regenerative approach through fat grafting. Gynecol. Oncol. 2015; 139(3): 471-5. https://dx.doi.org/10.1016/j.ygyno.2015.10.014.
45. Monreal J. Safety and efficacy of stromal vascular fraction enriched Fft grafting therapy for vulvar lichen sclerosus. Cureus. 2020; 12(2): e7096. https://dx.doi.org/10.7759/cureus.7096.
46. Pinheiro N.M., Crema V.O., Millan B.M., Carvalho F.A., Mendonça A.C. Comparison of the effects of carboxytherapy and radiofrequency on skin rejuvenation. J. Cosmet. Laser Ther. 2015; 17(3): 156-61. https://dx.doi.org/10.3109/14764172.2014.1003238.

Received 29.04.2020

Accepted 25.06.2020